WebS Kavanagh, et al., AML refractory to primary induction with Ida-FLAG has a poor clinical outcome. Leuk Res 68, 22–28 (2024). Crossref. PubMed. Google Scholar. 9. E Papaemmanuil, et al., Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 374, 2209–2221 (2016). WebStudy CC-90002-AML-001 is an open-label, Phase 1 dose escalation (Part A) and expansion (Part B), clinical study of CC-90002, administered by intravenous (IV) infusion, in subjects with relapsed and/or primary refractory AML and high-risk MDS.

Clinical Trial on Refractory/Relapse Acute Myeloid Leukemia: …

WebThere were 11 males and 11 females with a median age of 47.5 years (12–84 years). Among them, 8 patients were relapsed AML including 2 patients relapsed after HSCT and 14 patients were primary refractory AML including 4 secondary AML. The median number of cycles of previous chemotherapy was 4 (range, 2–10). WebIn another recent report, 22% of 168 patients with primary refractory AML who underwent … negatively impactful

Efficacy and toxicity of cladribine for the treatment of refractory ...

WebIntroduction: Acute myeloid leukemia [AML] is a heterogenous group of primary … WebApr 14, 2024 · Abstract. Background: Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are hematologic malignancies arising from immature myeloid progenitor cells in bone marrow. Depending on age and genetic disposition, as many as 40% to 60% of patients may have disease that is refractory to primary treatment, and of those who … WebIn primary relapse the response rates in AML and ALL are distinctively higher: In a retrospective study evaluating the outcome of children with primary relapsed or refractory acute myeloid leukemia a five-year survival rate of 34% was reported after a re-induction therapy with 6-thioguanine, cytarabine, doxorubicin, etoposide and mitoxantrone … negatively impacting thesaurus